News & Media

Recent updates from Arcutis.

October 4, 2021 Featured

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

September 30, 2021 Featured

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

September 28, 2021

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

September 27, 2021

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

September 9, 2021

Arcutis to Present at Upcoming Investor Conferences

September 2, 2021

Arcutis Announces Appointment of Keith Leonard to Board of Directors

August 25, 2021

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

August 23, 2021

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

August 5, 2021

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

August 2, 2021

Arcutis Announces Additions to its Investor Relations and Communications Team

July 21, 2021

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

July 12, 2021

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

Media Resources

Roflumilast Foam: Phase 2 Trial for the Treatment of Seborrheic Dermatitis

The Impact of Seborrheic Dermatitis

New England Journal of Medicine, Infographic / Backgrounder, July 2020

Media Contact

Amanda Shelton

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download